NeOnc Technologies (NTHI)has appointed Dr. David Ashley to its scientific advisory board. Dr. Ashley is the Rory David Deutsch Distinguished Professor of Neuro-Oncology and the Director of The Preston Robert Tisch Brain Tumor Center at Duke University.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTHI:
- NeOnc Technologies appoints Alexandra Miller to SAB
- NeOnc Technologies appoints Henry Friedman to SAB
- NeOnc Technologies to be featured on ‘Health Uncensored with Dr. Drew’
- NeOnc Technologies Advances to Phase II Brain Cancer Trial
- NeOnc receives FDA authorization to proceed with Phase II trial of NEO212